fPSA/tPSA及PSAD在前列腺疾病诊断中的价值

The Value of fPSA/tPSA and PSAD in the Diagnosis of Prostatic Diseases

目的探究游离PSA(fPSA)和总PSA(tPSA)的比值(fPSA/tPSA)及前列腺抗原密度(PSAD)在前列腺疾病诊断中的价值。方法收集前列腺炎、良性前列腺增生、经病理明确诊断的前列腺恶性肿瘤患者共458例的tPSA并计算各例fPSA/tPSA,PSAD值。结果 458例患者中52例Ⅰ,Ⅱ型前列腺炎组为6.01±3.25,0.31±0.22,0.24±0.33;75例Ⅲ,Ⅳ型前列腺炎组为4.16±1.03,0.24±0.15,0.20±0.17;234例良性前列腺增生组为17.253.87,0.31±0.27,0.35±0.12;97例前列腺癌组为51.35±49.23,0.13±0.11,0.69±0.12。结论fPSA/tPSA及PSAD的联合分析在前列腺疾病的诊断中明显优于单纯使用PSA。

Objective To explore fPSA/tPSA and PSAD＆#39;s value in the diagnosis of prostatic diseases.Meth-ods 458 patients with prostatic diseases were collected,including prostatitis,benign prostatic hyperplasia and the patho-logical diagnosis of prostate malignant tumor,and then calculated example fPSA/tPSA,PSAD values.Results Fifty-two cases of typeⅠⅡprostatitis were 6.01 ±3.25,0.31 ±0.22,0.24 ±0.33;75 cases of tpyeⅢ,Ⅳprostatitis group were 4.16 ±1.03,0.24 ±0.15,0.20 ±0.17;234 cases of benign prostatic hyperplasia group were 17.25 ±3.87,0.31 ±0. 27,0.35 ±0.12;97 cases of prostate cancer group were 51.35 ±49.23,0.13 ±0.11,0.69 ±0.12.Conclusion The conjoint analysis of fPSA/tPSA and PSAD in the diagnosis of prostate disease is superior to pure use of PSA.